Arena Pharma (ARNA) – Press Releases
-
Longboard Pharmaceuticals Announces the Appointment of Highly Accomplished Healthcare Executive Randall Kaye, M.D., as Chief Medical Officer
-
Longboard Pharmaceuticals Provides Corporate Update and Reports Full Year 2021 Financial Results
-
Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Arena Pharmaceuticals to Release Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update on February 23
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Longboard Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
ARENA PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of ARNA and Encourages Investors to Contact the Firm
-
Pfizer to Acquire Arena Pharmaceuticals
-
Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod CULTIVATE Study A
-
Longboard Pharmaceuticals Appoints Life Sciences Executive Dr. Jane Tiller to Board of Directors
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Longboard Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Arena Reports Third Quarter Financial Results and Key Program Updates
-
Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2021 Financial Results
-
Longboard Pharmaceuticals Announces Steven W. Spector Joins the Company as General Counsel
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Arena Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Corporate Update on November 4
-
Longboard Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference on September 28, 2021
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial
-
Arena Pharmaceuticals to Host Virtual R&D Investor Calls and Participate in Upcoming September Investor Conferences
-
Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2021 Financial Results
-
Arena Reports Second Quarter Financial Results and Key Program Updates
-
Second Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkers
-
Arena Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Corporate Update on August 5
-
Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory Diseases
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Arena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Steven Schoch Elected to Arena Pharmaceuticals Board of Directors
-
Arena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of Eosinophilic Esophagitis (EoE)
-
Arena Pharmaceuticals Announces First Participant Randomized in Phase 2 Trial Evaluating Temanogrel in Coronary Microvascular Obstruction (cMVO)
-
Arena Pharmaceuticals Earns "A" Rating from MSCI ESG, a Leading Rating Agency for Sustainable Investments
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Arena Pharmaceuticals Earns Prime Status from ISS ESG, a Leading Rating Agency for Sustainable Investments
-
Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2021 Financial Results
-
Arena Reports First Quarter Financial Results with Strong Cash Position and Continued Progress on Pipeline Over the Quarter
-
Arena Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Corporate Update on May 5
-
Arena Pharmaceuticals Presents Clinician and Patient Reported Outcomes Data from Phase 2b ADVISE Trial Evaluating Etrasimod in Adult Atopic Dermatitis During a Late-Breaking Session at American Academ
-
Arena Pharmaceuticals Releases Second Annual Environmental, Social and Governance (ESG) Report
-
Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial During Late-Breaking Research Session at American Academy of Dermatology Virtual Meeting Experience
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Longboard Pharmaceuticals Announces Pricing of Initial Public Offering
-
Arena Pharmaceuticals Reports Topline Results from Phase 2b CAPTIVATE Clinical Trial
-
Arena Reports Fourth Quarter Financial Results with Strong Liquidity Position and Maintained Pipeline Progress Over the Quarter
Back to ARNA Stock Lookup
